Abstract
Proteolysis mediated by matrix metalloproteinases (MMPs) and serine proteinases is associated with cancer invasion and metastasis. Activation of latent proMMPs, and especially the proforms of the type IV collagen degrading gelatinases A and B (proMMP-2 and proMMP-9), is thought to be a critical step in this process. We have recently found that human tumour-associated trypsin-2 is a potent activator of proMMP-9 and it also activates proMMP-2 in vitro. Trypsinogen, MMP-2, and MMP-9 are expressed in ovarian cancer. To elucidate the function of trypsin in vivo, we studied whether high concentrations of trypsinogen-1, trypsinogen-2, their α1-proteinase inhibitor (API) complexes, and tumour-associated trypsin inhibitor (TATI) are associated with proMMP-2 and proMMP-9 activation in ovarian tumour cyst fluids. Zymography and immunofluorometric analysis of 61 cyst fluids showed a significant association between high trypsin concentrations and the activation of MMP-9 (P= 0.003–0.05). In contrast, the trypsin concentrations were inversely associated with the activation of MMP-2 (P= 0.01–0.02). Immunohistochemical analysis of ovarian tumour tissue demonstrated expression of trypsinogen-2 and TATI in the secretory epithelium. MMP-2 was detected both in stromal and epithelial cells whereas MMP-9 was detected in neutrophils and macrophage-like cells in stromal and epithelial areas. These results suggest that trypsin may play a role in the regulation of the MMP-dependent proteolysis associated with invasion and metastasis of ovarian cancer. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Afzal S, Lalani E-N, Foulkes WD, Boyce B, Tickle S, Cardillo MR, Baker T, Pignatelli M and Stamp GW (1996) Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 74: 406–421
Afzal S, Lalani E-N, Poulsom R, Stubbs A, Rowlingson G, Sato H, Seiki M and Stamp GWH (1998) MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol 29: 155–165
Autio-Harmainen H, Karttunen T, Hurskainen T, Höyhtyä M, Kauppila A and Tryggvason K (1993) Expression of 72 kilodalton type IV collagenase (gelatinase A) in benign and malignant ovarian tumors. Lab Invest 69: 312–321
Benedet JL, Bender H, Jones, III H, Ngan HYS and Pecorelli S (2000) FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 70: 209–262
Bernhard EJ, Gruber SB and Muschel RJ (1994) Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase / collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci USA 91: 4293–4297
Boyd RS and Balkwill FR (1999) MMP-2 release and activation in ovarian carcinoma: the role of fibroblasts. Br J Cancer 80: 315–321
Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD and Balkwill FR (1993a) Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 67: 1126–1131
Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F (1993b) Levels of metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53: 5365–5369
De Nictolis M, Garbisa S, Lucarini G, Goteri G, Masiero L, Ciavattini A, Garzetti GG, Stetler-Stevenson WG, Fabris G, Biagini G and Prat J (1996) 72–kilodalton type IV collagenase, type IV collagen, and Ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and Serological study. Int J Gynecol Pathol 15: 102–109
Ferry G, Lonchampt M, Pennel L, de Nanteuil G, Canet E and Tucker GC (1997) Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett 402: 111–115
Fishman D, Bafetti LM, Banionis S, Kearns AS, Chilukuri K and Stack MS (1997) Production of extracellular matrix-degrading proteinases of primary cultures of human epithelial ovarian carcinoma cells. Cancer 80: 1457–1463
Fujimura T, Ohta T, Kitagawa H, Fushida S, Nishimura G-I, Yonemura Y, Elnemr A, Miwa K and Nakanuma Y (1998) Trypsinogen expression and early detection for peritoneal dissemination in gastric cancer. J Surg Oncol 69: 71–75
Furuya M, Ishikura H, Kawarada Y, Ogawa Y, Sakuragi N, Fujimoto S and Yoshiki T (2000) Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms. Gynecol Oncol 78: 106–112,doi: 10.1006/gyno.2000.5856
Garzetti GG, Ciavattini A, Lucarini G, Goteri G, de Nictolis M, Garbisa S, Masiero L, Romanini C and Graziella B (1995) Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res 15: 2799–2804
Hedström J, Leinonen J, Sainio V and Stenman U-H (1994) Time-resolved immunofluorometric assay of trypsin-2 complexed with a-1-antitrypsin in serum. Clin Chem 40: 1761–1765
Hedström J, Haglund C, Kemppainen E, Leinimaa M, Leinonen J and Stenman U-H (1999) Time-resolved immunofluorometric assay of trypsin-1 complexed with α1-antitrypsin in serum: increased immunoreactivity in patients with biliary tract cancer. Clin Chem 45: 1768–1773
Hirahara F, Miyagi Y, Miyagi E, Yasumitsu H, Koshikawa N, Nagashima Y, Kitamura H, Minaguchi H, Umeda M and Miyazaki K (1995) Trypsinogen expression in human ovarian carcinomas. Int J Cancer 63: 176–181
Hirahara F, Miyagi E, Nagashima Y, Miyagi Y, Yasumitsu H, Koshikawa N, Nakatani Y, Nakazawa T, Udagawa K, Kitamura H, Minaguchi H and Miyazaki K (1998) Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors. Gynecol Oncol 68: 162–165
Höyhtyä M, Hujanen E, Turpeenniemi-Hujanen T, Thorgeirsson U, Liotta LA and Tryggvason K (1990) Modulation of type-IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type-IV collagenase. Int J Cancer 46: 282–286
Höyhtyä M, Fridman R, Komarek D, Porter JK, Stetler-Stevenson WG, Liotta LA and Liang CM (1994) Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 56: 500–505
Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS and Mok SC (2000) Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 77: 369–376
Itkonen O, Koivunen E, Hurme M, Alfthan H, Schröder T and Stenman U-H (1990) Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med 115: 712–718
Juarez J, Clayman G, Nakajima M, Tanabe KK, Saya H, Nicolson GL and Boyd D (1993) Role and regulation of expression of 92-kDa type-IV collagenase (MMP-9) in 2 invasive squamous-cell-carcinoma cell lines of the oral cavity. Int J Cancer 55: 10–18
Kato Y, Nagashima Y, Koshikawa N, Miyagi Y, Yasumitsu H and Miyazaki K (1998) Production of trypsins by human gastric cancer cells correlates with their malignant phenotype. Eur J Cancer 34: 1117–1123
Kjeldsen L, Johnsen AH, Sengelov H and Borregaard N (1993) Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268: 10425–10432
Koivunen E, Huhtala M-L and Stenman U-H (1989) Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 264: 14095–14099
Koivunen E, Itkonen O, Halila H and Stenman U-H (1990) Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res 50: 2375–2378
Koivunen E, Ristimäki A, Itkonen O, Osman S, Vuento M and Stenman U-H (1991a) Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res 51: 2107–2112
Koivunen E, Saksela O, Itkonen O, Osman S, Huhtala M-L and Stenman U-H (1991b) Human colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogen. Int J Cancer 47: 592–596
Koshikawa N, Yasumitsu H, Nagashima Y, Umeda M and Miyazaki K (1994) Identification of one-and two-chain forms of trypsinogen 1 produced by a human gastric adenocarcinoma cell line. Biochem J 303: 187–190
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685
Levy AT, Cioce V, Sobel ME, Garbisa S, Grigioni WF, Liotta LA and Stetler-Stevenson SW (1991) Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res 51: 439–444
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S (1980) Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67–68
Lukkonen A, Sorsa T, Salo T, Tervahartiala T, Koivunen E, Golub L, Simon S and Stenman U-H (2000) Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int J Cancer 86: 577–581
Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S and Mignatti P (1997) Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16: 2319–2332
Mignatti P, Robbins E and Rifkin DB (1986) Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell 47: 487–498
Miyata S, Miyagi Y, Koshikawa N, Nagashima Y, Kato Y, Yasumitsu H, Hirahara F, Misugi K and Miyazaki K (1998) Stimulation of cellular growth and adhesion to fibronectin and vitronectin in culture and tumorigenicity in nude mice by overexpression of trypsinogen in human gastric cancer cells. Clin Exp Metastasis 16: 613–622
Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC and Stack MS (1994) Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 56: 552–559
Naylor MS, Stamp GW, Davies BD and Balkwill FR (1994) Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 58: 50–56
Nielsen BS, Timshel S, Kjeldsen L, Sehested M, Pyke C, Borregaard N and Dano K (1996) 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer 65: 57–62
Ohlsson K (1988) Acute pancreatitis. Biochemical, pathophysiological and therapeutical aspects. Acta Gastroenterol Belg 51: 3–12
Osman S, Turpeinen U, Itkonen O and Stenman U-H (1993) Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods 161: 97–106
Pyke C, Ralfkiær E, Tryggvason K and Danø K (1993) Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol 142: 359–365
Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E and Seiki M (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370: 61–65
Sorsa T, Salo T, Koivunen E, Tyynelä J, Konttinen YT, Bergmann U, Tuuttila A, Niemi E, Teronen O, Heikkilä P, Tschesche H, Leinonen J, Osman S and Stenman U-H (1997) Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem 272: 21067–21074
Stenman U-H, Koivunen E and Itkonen O (1991) Biology and function of tumor-associated trypsin inhibitor, TATI. Scand J Clin Lab Invest Suppl 207: 5–9
Terada T, Ohta T, Minato H and Nakanuma Y (1995) Expression of pancreatic trypsinogen/trypsin and cathepsin B in human cholangiocarcinomas and hepatocellular carcinomas. Hum Pathol 26: 746–752
Tokuraku M, Sato H, Murakami S, Okada Y, Watanabe Y and Seiki M (1995) Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlate with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer 64: 355–359
Tryggvason K, Höyhtyä M and Salo T (1987) Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 907: 191–217
Turpeenniemi-Hujanen T, Ronnberg L, Kauppila A and Puistola U (1992) Laminin in the human embryo implantation: analogy to the invasion by malignant cells. Fertil Steril 58: 105–13
Ueda G, Shimizu C, Tanaka Y, Inoue M, Tanizawa O, Ogawa M and Mori T (1989) Immunohistochemical demonstration of pancreatic secretory trypsin inhibitor in gynecologic tumors. Gynecol Oncol 32: 37–40
Väisänen A, Kallioinen M, Taskinen PJ and Turpeenniemi-Hujanen T (1998) rognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 186: 51–58
Venesmaa P, Stenman U-H, Forss M, Leminen A, Lehtovirta P, Vartiainen J and Paavonen J (1998) Pre-operative serum level of tumour-associated trypsin inhibitor and residual tumor size as prognostic indicators in Stage III epithelial ovarian cancer. Br J Obstet Gynaecol 105: 508–511
Vergote IB, Kærn J, Abeler VM, Pettersen EO, De Vos LN and Tropé CG (1993) Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol 169: 40–52
Westerlund A, Hujanen E, Puistola U and Turpeenniemi-Hujanen T (1997) Fibroblasts stimulate human ovarian cancer cell invasion and expression of 72-kDa gelatinase A (MMP-2). Gynecol Oncol 67: 76–82
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Paju, A., Sorsa, T., Tervahartiala, T. et al. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br J Cancer 84, 1363–1371 (2001). https://doi.org/10.1054/bjoc.2001.1806
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2001.1806
Keywords
This article is cited by
-
Comparative study of the binding between chlorogenic acid and four proteins by isothermal titration calorimetry, spectroscopy and docking methods
Pharmacological Reports (2022)
-
A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diagnosis of metastasis in patients with breast cancer
Tumor Biology (2014)
-
Matrix metalloprotein-9 activation under cell-to-cell interaction between endothelial cells and monocytes: possible role of hypoxia and tumor necrosis factor-α
Heart and Vessels (2012)
-
Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development
Asian Journal of Andrology (2011)
